Cypress Wealth Services’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$239K Sell
1,695
-253
-13% -$38.4K 0.03% 382
2026
Q2
$305K Sell
1,948
-151
-7% -$22.6K 0.04% 336
2026
Q1
$321K Sell
2,099
-507
-19% -$77.7K 0.05% 291
2025
Q4
$359K Buy
2,606
+480
+23% +$62.9K 0.05% 260
2025
Q3
$273K Buy
2,126
+4
+0.2% +$488 0.04% 271
2025
Q2
$257K Buy
2,122
+138
+7% +$15.6K 0.05% 263
2025
Q1
$221K Buy
+1,984
New +$211K 0.04% 258
2024
Q4
– Sell
-1,850
Closed -$213K – 296
2024
Q3
$213K Buy
+1,850
New +$210K 0.04% 257
2024
Q2
– Sell
-2,084
Closed -$202K – 271
2024
Q1
$202K Buy
+2,084
New +$214K 0.05% 248
2021
Q2
– Sell
-2,456
Closed -$210K – 300
2021
Q1
$210K Buy
2,456
+93
+4% +$8.35K 0.04% 274
2020
Q4
$223K Buy
+2,363
New +$206K 0.05% 259

Other funds holding NVS

Cypress Wealth Services's NVS Position: Q3 2026 in Review

Cypress Wealth Services reduced its Novartis (NVS) stake by 13% in Q3 2026, selling an estimated $38.4K and leaving 1,695 shares worth $239K. The position accounts for 0.03% of the portfolio, ranked #382.

Cypress Wealth Services first reported a position in NVS in Q4 2020 and has held it in 11 quarters since. The position peaked at $359K in Q4 2025. 839 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Cypress Wealth Services held 1,695 shares of Novartis worth $239K as of Q3 2026.
  • Cypress Wealth Services sold 253 Novartis shares in Q3 2026, an estimated $38.4K.
  • Novartis made up 0.03% of Cypress Wealth Services's portfolio in Q3 2026, its #382 holding.
  • Cypress Wealth Services first reported a position in Novartis in Q4 2020 and has held it in 11 quarters since.
  • Cypress Wealth Services's Novartis position peaked at $359K in Q4 2025.
  • 839 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Cypress Wealth Services's 13F filing for Q3 2026, filed 21 Oct 2026.